Abeona Therapeutics Inc
abeonatherapeutics.comWhat Do They Do?
Sells ZEVASKYN, a gene-modified cell therapy for RDEB wounds, to qualified treatment centers, and develops gene therapies for inherited eye diseases.
10-K for FY2025, filed Mar 17, 2026Abeona Therapeutics Inc., a Delaware corporation (together with our subsidiaries, “we,” “our,” “Abeona” or the “Company”), is a…View ↗
ZEVASKYN® is manufactured at our current Good Manufacturing Practices (“cGMP”) manufacturing facility in Cleveland, Ohio. Treatments are…View ↗
The Company’s development portfolio also features adeno-associated virus (“AAV”)-based gene therapies designed to treat ophthalmic diseases…View ↗
ZEVASKYN® is a commercial product comprised of autologous epidermal gene-modified sheets in which a functioning COL7A1 gene is inserted…View ↗
The Company generates product revenue from sales of ZEVASKYN® in the United States. The Company ships and sells ZEVASKYN® directly to…View ↗
How Do They Make Money?
Licensing revenue (58% of FY2025 revenue) comes from companies paying for rights to develop, manufacture or commercialize product candidates, through upfront fees, reimbursements, option fees, milestones or royalties. Qualified treatment centers pay for ZEVASKYN when its final quality inspection is complete.
10-K for FY2025, filed Mar 17, 2026
-
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗
$5.8M
-
10-K for FY2025, filed Mar 17, 2026
$5.8M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
42% |
Product, FY2025
$2.4M Sources
|
Sold outright |
|
License
Licensed
10-K for FY2025, filed Mar 17, 2026 |
58% |
License, FY2025
$3.4M Sources
|
Licensed |
Who Are Their Customers?
Qualified treatment centers buy ZEVASKYN directly; other companies license rights to develop, manufacture and commercialize product candidates.
10-K for FY2025, filed Mar 17, 2026
10-K for FY2025, filed Mar 17, 2026
For the year ended and as of December 31, 2025 % of Revenue % of Accounts Receivable Customer 1 48.1 % 51.2 % Customer 2 45.8 % 48.8 %View ↗
Do Revenues Turn Into Profits?
Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$84.3M.
How Are They Changing?
Growing. Revenue grew 94% in 4 years, from $3M in FY2021 to $5.8M in FY2025, about 18% a year.
From development to sales
The older report described the lead RDEB therapy as a clinical-stage program intended for possible commercialization; the latest report describes an approved product being commercialized through qualified treatment centers.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 17, 2026
Loading...
